BYL719, a selective inhibitor of phosphoinositide 3-Kinase [alpha], enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer

KRAS is frequently mutated in non-small cell lung cancers (NSCLC), resulting in activation of the MEK/ERK pathway. Because there are currently no drugs that target oncogenic KRAS, MEK inhibitors have been tested clinically as a possible treatment option for patients with NSCLC. However, KRAS-mutant...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 2015-02, Vol.33 (1), p.12
Main Authors: Ku, Bo Mi, Jho, Eun Hye, Bae, Yeon-hee, Sun, Jong-mu, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-ju
Format: Article
Language:English
Subjects:
Antibodies
Biomedical research
Biotechnology
Cancer therapies
Cell cycle
Cell growth
Combination therapy
Drugs
Inhibitor drugs
Kinases
Laboratory animals
Lung cancer
Mutation
Pharmaceutical sciences
Phosphatase
Phosphorylation
Proteins
Studies
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:KRAS is frequently mutated in non-small cell lung cancers (NSCLC), resulting in activation of the MEK/ERK pathway. Because there are currently no drugs that target oncogenic KRAS, MEK inhibitors have been tested clinically as a possible treatment option for patients with NSCLC. However, KRAS-mutant cancers exhibit resistance to MEK inhibitors. Therefore, a combinational strategy is necessary for effective therapy. To address this, we investigated the therapeutic effects of combining selumetinib, a MEK1/2 inhibitor, with BYL719, a PI3K[alpha] inhibitor. We evaluated the effects of selumetinib and BYL719 in vitro and in vivo in NSCLC cell lines. The combination of BYL719 and selumetinib resulted in synergistic cytotoxic activity compared with the single agents alone in KRAS-mutant NSCLC cells. At the molecular level, we found that AKT activation strongly influenced the sensitivity of KRAS-mutant NSCLC cells to selumetinib. Selumetinib upregulated phospho-AKT and phosphorylated BAD at ser136, which is responsible for intrinsic drug resistance in KRAS-mutant NSCLC cells. In contrast, inhibition of the PI3K/AKT pathway by BYL719 hindered selumetinib-induced BAD phosphorylation and increased the antitumor efficacy of selumetinib. Furthermore, selumetinib and BYL719 combination therapy showed synergy in the suppression of A549 xenograft tumor growth. On analysis of the pharmacodynamics, selumetinib and BYL719 together resulted in effective inhibition of both p-ERK and p-AKT expression in tumor tissue. Taken together, these data suggest that combination treatment with selumetinib and BYL719 is a promising therapeutic approach to overcoming resistance to MEK inhibitors.
ISSN:0167-6997
1573-0646
DOI:10.1007/s10637-014-0163-9